Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QuickStrip Medical Cannabis is an oral thin film drug delivery platform developed by Rapid Dose Therapeutics. It utilizes a proprietary fast-dissolving strip technology to deliver micronized cannabinoids, including tetrahydrocannabinol (THC) and cannabidiol (CBD), through the sublingual or buccal mucosa. This delivery method allows the active ingredients to enter the bloodstream directly, bypassing the gastrointestinal tract and first-pass metabolism in the liver, which results in a more rapid onset of action compared to traditional oral ingestion. The product is designed to alleviate symptoms associated with chronic pain, anxiety, sleep disorders, and various neurological conditions. It has received regulatory approval from ANVISA in Brazil and is licensed for the medical cannabis market in Canada.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on QuickStrip Medical Cannabis.